Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase I... oleh Hu XS, Han XH, Yang S, Li N, Wang L, Song YY, Mu H, Shi YK